Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report |
| |
| Authors: | Sean Xiang Wang Sadhna Verma John R Pancoast Olivier Rixe |
| |
| Institution: | (1) Division of Hematology/Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA;(2) Department of Veterans Affairs Medical Center, Cincinnati, OH, USA;(3) Southeastern Kentucky Cancer Center, Corbin, KY, USA;(4) Department of Radiology, Section of Abdominal Imaging, University of Cincinnati Medical Center, Cincinnati, OH, USA;(5) Division of Hematology/Oncology, University of Cincinnati, Cincinnati, OH, USA;(6) Department of VAMC, University of Cincinnati College of Medicine, Cincinnati, OH, USA;(7) Department of Veterans Affairs Med. Center, Hematology/Oncology Section, 3200 Vine Street, B234f, mc 111-D, Cincinnati, OH 45220, USA |
| |
| Abstract: | Hepatocellular carcinoma (HCC) is a highly aggressive cancer. For patients who are diagnosed with advanced stage disease that
are not surgical candidates, the disease is universally lethal. Advance has been made to extend survival with molecular target
therapy, but durable complete responses are extremely rare. We report an unusual case where a 74-year-old patient with unresectable
HCC received eight months of reduced-dose of sorafenib, a tyrosine kinase inhibitor, and achieved a durable complete remission.
At the most recent follow up, he remains in remission 16 months after cessation of treatment, without clinical or imaging
evidence of disease recurrence. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
